Antisense now makes sense: dual modulation of androgen-dependent transcription by CTBP1-AS.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed, 14 citations in OpenAlex.

1. Clinical significance and biological roles of lncRNA CTBP1-AS in polycystic ovary syndrome.Journal of ovarian research · 2024
   Article
2. A novel molecular mechanism for a long non-coding RNA PCAT92 implicated in prostate cancer.Oncotarget · 2018
   Article
3. Androgen Receptor Coregulator CTBP1-AS Is Associated With Polycystic Ovary Syndrome in Chinese Women: A Preliminary Study.Reproductive sciences (Thousand Oaks, Calif.) · 2015
   Article
4. Circulating Long Noncoding RNA as a Potential Target for Prostate Cancer.International journal of molecular sciences · 2015
   Review

Corrections and comments

• Comment on
  Androgen-responsive long noncoding RNA CTBP1-AS promotes prostate cancer.2013

Authors and funding

2 authors at 2 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as